论文信息 - Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules. - 字舞流文

Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules.

J. Jett | S. Mandrekar | A. Adjei | K. Rowland | S. Nair | S. Kuross | P. Steen | N. Reuter | S. Hillman | S. Schild